AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02315352
Drug: Cesol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cesol® tablet at a dose of 150 mg crushed in water
Trial: NCT00947557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral administration once daily on background of glimepiride with or without metformin
Trial: NCT00306696
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00793000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match 75 mg oral dose (prepared solution), given once
Trial: NCT00793000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match 150 mg oral dose (prepared solution), given once
Trial: NCT00793000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match 300 mg oral dose (prepared solution), given once
Trial: NCT00793000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match 750 mg oral dose (prepared solution), given once
Trial: NCT03081208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dispersible tablets for single oral administration
Trial: NCT03660943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving Placebo Injection
Trial: NCT03660943
Drug: CNTX-4975-05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving CNTX-4975-05 Injection
Trial: NCT00793000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match 1000 mg oral dose (prepared solution), given once
Trial: NCT04411082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of once daily Placebo
Trial: NCT02401529
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg/kg/day for 7 days then tapering for next 7 days
Trial: NCT02401529
Drug: IV saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline
Trial: NCT01755286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection
Trial: NCT01755286
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated single intratympanic injection
Trial: NCT02182882
Drug: GINSANA
RxNorm normalized name: Ginsana 200mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00793000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match 1250 mg oral dose (prepared solution), given once
Trial: NCT00793000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match 1500 mg oral dose (prepared solution), given once
Trial: NCT01691989
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses once a day for 26 weeks
Trial: NCT01470313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
Trial: NCT04056169
Drug: high-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 20 mg once a day for 6 months
Trial: NCT04056169
Drug: low-dose rosuvastatin plus ezetimibe
RxNorm normalized name: ezetimibe / rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
Trial: NCT02037893
Drug: Antipyrine Otic Solution
RxNorm normalized name: antipyrine Otic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
Trial: NCT02037893
Drug: Benzocaine Otic Solution
RxNorm normalized name: Benzocaine Otic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benzocaine 14 mg and glycerine dehydrated to 1.0 mL
Trial: NCT02037893
Drug: Placebo Otic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo otic solution will be glycerin that is dehydrated
Trial: NCT04454424
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study intervention BAY1817080 will be administered orally with tablet(s).
Trial: NCT01089556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
Trial: NCT02783638
Drug: YHD1119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 by 2
Trial: NCT03040219
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT02896192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily SC injection
Trial: NCT01097980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00551213
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00551213
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
Trial: NCT00551213
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
Trial: NCT01922934
Drug: Obesity pharmacotherapy
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine or phentermine-topiramate (Qsymia)
Trial: NCT01061372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
Trial: NCT00292812
Drug: Nutritional supplementation (nucleotides)
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03292302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01890967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01890967
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02945306
Drug: Watchful waiting with supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of widely prescribed medicines to treat associated conditions
Trial: NCT01036087
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
Trial: NCT03805360
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
Trial: NCT02343614
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00714337
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
Trial: NCT00855218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
Trial: NCT00688441
Drug: Nasal CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily during the 14 day Treatment Period
Trial: NCT00688441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of the study drug dispenser at the same frequency as the active arm
Trial: NCT04364945
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of remifentanil 0.1-0.2 mcg/kg/min
Trial: NCT03971695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule or Oral solution
Trial: NCT03905811
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule by mouth daily at bedtime
Trial: NCT00714337
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
Trial: NCT00445900
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00790608
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
Trial: NCT00837551
Drug: WBI-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
Trial: NCT04400266
Drug: Mealatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 3mg once nightly
Trial: NCT00044993
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02333851
Drug: Mixtard 30:70 Novonordisk® twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premixed insulin twice daily before breakfast and before dinner
Trial: NCT02333851
Drug: Lantus® once daily and Apidra® before meals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
Trial: NCT00549497
Drug: GW870086X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03415178
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT00523432
Drug: CCI-779 (temsirolimus)
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 25mg dose via IV infusion.
Trial: NCT03607539
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
Trial: NCT01324115
Drug: NG-nitro-L-arginine
RxNorm normalized name: NG-nitro-L-arginine methyl ester
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02991001
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02273167
Drug: NER1006, 2-Day Split-Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Trial: NCT02273167
Drug: NER1006,1-Day Morning Split-Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid.
Trial: NCT02273167
Drug: MOVIPREP, 2-Day Split-Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
Trial: NCT01992042
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
Trial: NCT00679237
Drug: betablocker, diuretics, ACEI, ARB,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blood pressure control according to ESC guidelines
Trial: NCT01769235
Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
Trial: NCT02424344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
Trial: NCT03128203
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline, intranasally administrated
Trial: NCT01769235
Drug: Acanya® Gel, 1.2%/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
Trial: NCT03311555
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
Trial: NCT01445639
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as placebo
Trial: NCT02262143
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 10 mg, qd, po
Trial: NCT02146651
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.2U/Kg body weight injected subcutaneously
Trial: NCT00839228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet bd for 3 months
Trial: NCT01456663
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04533568
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
Trial: NCT02160626
Drug: A-101 (40) Topical Solution
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-101 (40) Topical Solution - high dose
Trial: NCT02160626
Drug: A-101 (32.5) Topical Solution
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-101 (32.5) Topical Solution - low dose
Trial: NCT04324229
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
Trial: NCT01353235
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
Trial: NCT01746173
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01746173
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01689337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Trial: NCT02431013
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg on Day 1 \& Day 8.
Trial: NCT02431013
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg on Day 1 \& Day 8.
Trial: NCT02657330
Drug: SBP-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous drug, escalating dose cohorts
Trial: NCT01905696
Drug: Oral N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01182025
Drug: Xiyanping Injection
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor.
Trial: NCT03449459
Drug: aerosol inhaled amikacin
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time.
Trial: NCT02040233
Drug: BAY1067197 (10 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg BAY1067197 for 7 d treatment once daily as oral application
Trial: NCT02040233
Drug: BAY1067197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
Trial: NCT02040233
Drug: Placebo (10 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Placebo for 7 d treatment once daily as oral application
Trial: NCT01703351
Drug: Fentanyl 500mcg + acupan 160mg + nasea 0.6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
Trial: NCT03485625
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
Trial: NCT02641054
Drug: CVXL-0107
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02641054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02641054
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02953730
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02040233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
Trial: NCT02135952
Drug: MTZ+AMX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
Trial: NCT01122251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Lercanidipine and Valsartan
Trial: NCT01607658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Trial: NCT01607658
Drug: Low dose TBS-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
Trial: NCT04459247
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liquid formulation of 60000 IU
Trial: NCT02344563
Drug: Mepem
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00343447
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01498679
Drug: GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
Trial: NCT01498679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once daily in the evening via a NDPI
Trial: NCT04525300
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification